Literature DB >> 12414782

Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).

F Portaels1, J Aguiar, M Debacker, C Steunou, C Zinsou, A Guédénon, W M Meyers.   

Abstract

Mycobacterium ulcerans disease, or Buruli ulcer (BU), causes significant morbidity in West Africa. In 233 consecutive, laboratory-confirmed samples from BU patients in Benin whose Mycobacterium bovis BCG scar status was known, 130 children (<15 years old) and 75 adults had a neonatal BCG vaccination scar. Of 130 children with BCG scars, 10 (7.7%) had osteomyelitis, while 3 of 9 children without BCG scars (33.3%) had osteomyelitis. Our observations support the conclusion that having a BCG vaccination scar provides significant protection against M. ulcerans osteomyelitis in children with BU disease.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12414782      PMCID： PMC130119          DOI： 10.1128/cdli.9.6.1389-1391.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  14 in total

1.  The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function.

Authors:  A A Pahlevan; D J Wright; C Andrews; K M George; P L Small; B M Foxwell
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

2.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.

Authors: 
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

3.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence.

Authors:  K M George; D Chatterjee; G Gunawardana; D Welty; J Hayman; R Lee; P L Small
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans.

Authors:  M Pimsler; T A Sponsler; W M Meyers
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

5.  The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda.

Authors:  P G Smith; W D Revill; E Lukwago; Y P Rykushin
Journal:  Trans R Soc Trop Med Hyg       Date:  1976       Impact factor: 2.184

6.  Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo.

Authors:  W M Meyers; N Tignokpa; G B Priuli; F Portaels
Journal:  Br J Dermatol       Date:  1996-06       Impact factor: 9.302

7.  [Buruli ulcer: risk of bone involvement! Apropos of 33 cases observed in Benin].

Authors:  V Lagarrigue; F Portaels; W M Meyers; J Aguiar
Journal:  Med Trop (Mars)       Date:  2000

8.  Immune response to infection with Mycobacterium ulcerans.

Authors:  T M Gooding; P D Johnson; D E Campbell; J A Hayman; E L Hartland; A S Kemp; R M Robins-Browne
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

9.  BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda.

Authors: 
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

10.  The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection.

Authors:  J L Stanford; W D Revill; W J Gunthorpe; J M Grange
Journal:  J Hyg (Lond)       Date:  1975-02
View more
  19 in total

Review 1.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 2.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

3.  Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice.

Authors:  Martinha S Oliveira; Alexandra G Fraga; Egídio Torrado; António G Castro; João P Pereira; Adhemar Longatto Filho; Fernanda Milanezi; Fernando C Schmitt; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice.

Authors:  Audrey Tanghe; Pierre-Yves Adnet; Tatiana Gartner; Kris Huygen
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

5.  Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.

Authors:  F Portaels; J Aguiar; M Debacker; A Guédénon; C Steunou; C Zinsou; W M Meyers
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic.

Authors:  Daniel M N Okenu; Lazarus O Ofielu; Kirk A Easley; Jeannette Guarner; Ellen A Spotts Whitney; Pratima L Raghunathan; Ymkje Stienstra; Kwame Asamoa; Tjip S van der Werf; Winette T A van der Graaf; Jordan W Tappero; David A Ashford; C Harold King
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

7.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.

Authors:  Ghislaine Prévot; Eliane Bourreau; Herve Pascalis; Roger Pradinaud; Audrey Tanghe; Kris Huygen; Pascal Launois
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

Review 8.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

9.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

10.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.